Current Oncology Reports最新文献_第3页

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer. 非典型子宫内膜增生症和早期子宫内膜癌的保宫治疗方案。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-03 DOI: 10.1007/s11912-024-01603-9

Naomi N Adjei, Mikayla Borthwick Bowen, Roni Nitecki Wilke, Melinda S Yates, Shannon N Westin

{"title":"Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.","authors":"Naomi N Adjei, Mikayla Borthwick Bowen, Roni Nitecki Wilke, Melinda S Yates, Shannon N Westin","doi":"10.1007/s11912-024-01603-9","DOIUrl":"10.1007/s11912-024-01603-9","url":null,"abstract":"Purpose of review: This review aims to synthesize available literature on uterine-conserving treatment options for atypical endometrial hyperplasia and grade 1 endometrial carcinoma while highlighting remaining unanswered questions.Recent findings: The need for uterine-conserving treatment options for atypical endometrial hyperplasia and grade 1 endometrial carcinoma is growing with the increasing number of cases in younger patients or those who cannot undergo surgery. We reviewed the oncological and reproductive outcomes associated with endocrine therapies used for atypical endometrial hyperplasia and grade 1 endometrial carcinoma. The rising prevalence of delayed childbearing, obesity, and diabetes in reproductive-age individuals and of medical comorbidities associated with high surgical risk continues to amplify the demand for uterine-conserving therapies. Appropriate patient selection for such therapies is imperative to maximize likelihood of treatment response. The ideal candidates are patients with atypical endometrial hyperplasia or early-stage, low-grade endometrial cancer with no evidence of myometrial invasion or extrauterine disease. The most accepted conservative therapeutic approach is hormonal therapy with close surveillance, with or without eventual hysterectomy following childbearing or failure of treatment. Further prospective and randomized trials are needed to address optimal patient and treatment selection, as well as the use of molecular profiling for treatment individualization and prognostication.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1367-1379"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic. 远程医疗在神经肿瘤学中的应用：COVID-19 大流行后的单个机构经验评述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-07-31 DOI: 10.1007/s11912-024-01588-5

Ugur Sener, Joon Uhm, Tufia Haddad, Joshua Pritchett

{"title":"Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.","authors":"Ugur Sener, Joon Uhm, Tufia Haddad, Joshua Pritchett","doi":"10.1007/s11912-024-01588-5","DOIUrl":"10.1007/s11912-024-01588-5","url":null,"abstract":"Purpose: During the COVID-19 pandemic, regulatory and reimbursement policy changes provided patients improved access to neuro-oncology by telehealth. Here we discuss benefits and limitations of telehealth use in neuro-oncology. We review utilization of telemedicine services following the COVID-19 pandemic.Recent findings: Utilization of telemedicine by neuro-oncology during the COVID-19 pandemic was 52%, compared to 27-29% for other solid tumors groups. Following the pandemic, between January 2021 and April 2024, telehealth utilization has remained high in neuro-oncology with approximately 30% of all visits completed by telemedicine, compared to 10-15% for other solid tumor groups. The striking difference between telehealth visit utilization in neuro-oncology and general medical oncology even after expiration of the COVID-19 Public Health Emergency expiration and end of pandemic-related restrictions, underscores the potential value of convenient access to care for patients with central nervous system tumors. Given widespread use of telehealth in neuro-oncology, prospective evaluation to determine the safety, usability, and acceptance of video-enabled, telehealth visits is critical. Such data may lead to broader adoption of telehealth, lead to regulatory and reimbursement reform for telehealth sustainability, and improve clinical trial access and accruals.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1271-1276"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Identify and Manage High-Risk Smoldering Multiple Myeloma. 如何识别和管理高风险多发性骨髓瘤。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-23 DOI: 10.1007/s11912-024-01596-5

Tarek H Mouhieddine

引用次数: 0

Prevention of Ovarian Cancer: Where are We Now and Where are We Going? 预防卵巢癌：我们的现状和未来？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-08 DOI: 10.1007/s11912-024-01587-6

Isabel V Rodriguez, Talayeh Ghezelayagh, Kathryn P Pennington, Barbara M Norquist

引用次数: 0

Return to Intended Oncological Therapy: State of the Art and Perspectives. 回归肿瘤治疗的初衷：技术现状与前景。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1007/s11912-024-01594-7

Nicolas A Cortes-Mejia, Heather A Lillemoe, Juan P Cata

引用次数: 0

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? 转移性 RAS 野生型左侧结直肠癌的一线疗法：是否每个人都应接受抗 EGFR 治疗？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-11 DOI: 10.1007/s11912-024-01601-x

Marco Airoldi, Michela Bartolini, Roberta Fazio, Sara Farinatti, Valentina Daprà, Armando Santoro, Alberto Puccini

{"title":"First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?","authors":"Marco Airoldi, Michela Bartolini, Roberta Fazio, Sara Farinatti, Valentina Daprà, Armando Santoro, Alberto Puccini","doi":"10.1007/s11912-024-01601-x","DOIUrl":"10.1007/s11912-024-01601-x","url":null,"abstract":"Purpose of review: This narrative review explores the efficacy and applicability of anti-EGFR therapy as the first-line treatment for patients with RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC). It critically examines current guidelines, along with recent evidence in the literature, to assess whether it should be universally applied.Recent findings: Recent evidences highlight the variability of the response to anti-EGFR therapies due to molecular diversity and several clinical factors, such as RAS mutational status and primary tumor location. Anti-EGFR plus chemotherapy is the standard first-line treatment for most patients with MSS, RAS-WT, left-sided mCRC. Whether this combination is the best treatment for these patients remains an open question. This review delves into the role of EGFR inhibition in mCRC, focusing on clinical factors and the knowledge of biology, molecular targets, and biomarkers. It underscores the crucial role of a personalized approach, empowering healthcare providers and equipping them with the confidence to make informed decisions.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1489-1501"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AML in the Elderly - When less may be more. 老年人的急性髓细胞白血病--少即是多。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-17 DOI: 10.1007/s11912-024-01604-8

Eric S Winer, Richard M Stone

引用次数: 0

Unveiling the Hidden Links: Periodontal Disease, Fusobacterium Nucleatum, and Cancers. 揭开隐藏的联系：牙周病、核酸镰刀菌和癌症。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1007/s11912-024-01591-w

Elahe Akbari, Joel B Epstein, Firoozeh Samim

{"title":"Unveiling the Hidden Links: Periodontal Disease, Fusobacterium Nucleatum, and Cancers.","authors":"Elahe Akbari, Joel B Epstein, Firoozeh Samim","doi":"10.1007/s11912-024-01591-w","DOIUrl":"10.1007/s11912-024-01591-w","url":null,"abstract":"Purpose of review: Fusobacterium nucleatum (F. nucleatum), an anaerobic, gram-negative microbe, commonly found in human dental biofilm and the gut flora. It has long been known to have a higher concentration in periodontal disease and has recently been implicated in both oral and distant cancers such as colorectal, gastrointestinal, esophageal, breast, pancreatic hepatocellular, and genitourinary cancers. However, the mechanism of its involvement in the development of cancer has not been fully discussed. This review aims to cover biological molecular and clinical aspects of F. nucleatum and cancers.Recent findings: Studies indicate F. nucleatum promotes tumor development through chronic inflammation, immune evasion, cell proliferation activation, and direct cell interactions, as in oral squamous cell carcinoma (OSCC). In colorectal cancer (CRC), F. nucleatum contributes to tumorigenesis through β-catenin signaling and NF-κB activation. It also induces autophagy, leading to chemoresistance in CRC and esophageal cancers, and enhances tumor growth and metastasis in breast cancer by reducing T-cell infiltration. F. nucleatum is linked to carcinogenesis and increased bacterial diversity in OSCC, with improved oral hygiene potentially preventing OSCC. F. nucleatum triggers cancer by causing mutations and epigenetic changes through cytokines and reactive oxygen species. It also promotes chemoresistance in CRC. F. nucleatum may potentially serve as a diagnostic tool in various cancers, with non-invasive detection methods available. Further investigation is needed to discover its potential in the diagnosis and treatment of OSCC and other cancers.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1388-1397"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver Cancer Etiology: Old Issues and New Perspectives. 肝癌病因学：老问题与新视角。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1007/s11912-024-01605-7

Jian-Guo Chen, Yong-Hui Zhang, Jian-Hua Lu, Thomas W Kensler

{"title":"Liver Cancer Etiology: Old Issues and New Perspectives.","authors":"Jian-Guo Chen, Yong-Hui Zhang, Jian-Hua Lu, Thomas W Kensler","doi":"10.1007/s11912-024-01605-7","DOIUrl":"10.1007/s11912-024-01605-7","url":null,"abstract":"Purpose of review: This review aims to synthesize the old issues and current understandings of the etiology of liver cancer, focusing on the diverse causative factors influenced by geographical, socioeconomic, and lifestyle variations across different regions.Recent findings: We highlight significant geographic disparities in liver cancer risk factors. While hepatitis B and C viruses, aflatoxin exposure, and alcohol consumption remain globally established contributors; metabolic dysfunction-associated steatotic liver disease and metabolic syndromes are increasingly prominent in the West. Chronic HBV and aflatoxin continue to dominate as risk factors in Asia and Africa. Dietary factors, metabolic diseases like diabetes and obesity, genetic predispositions, environmental risk factors and lifestyle choices such as smoking and alcohol use play substantial roles in specific populations. Protective factors like coffee and tea consumption, along with aspirin use, vegetables and fruits have shown potential in reducing HCC risk, although findings vary by population and dietary habits. Liver cancer etiology is influenced by various factors that differ by region. Established risk factors include hepatitis B and C, aflatoxin, and alcohol. Emerging risks, such as metabolic dysfunction-associated steatotic liver disease, are more prevalent in Western countries, while aflatoxin and HBV remains significant in Asia and Africa. Diet, metabolic conditions like diabetes and obesity, genetic predispositions, and lifestyle choices also play crucial roles. Coffee, tea, aspirin, vegetables, and fruits may reduce HCC risk, but effectiveness varies. Future research should integrate epidemiology, genetics, and nutrition, with global cooperation and data sharing essential for effective cancer control strategies.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1452-1468"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine. 大麻素在促进癌症治疗中的作用：来自循证医学的启示。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-07 DOI: 10.1007/s11912-024-01589-4

Magdalena Skórzewska, Katarzyna Gęca

{"title":"The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.","authors":"Magdalena Skórzewska, Katarzyna Gęca","doi":"10.1007/s11912-024-01589-4","DOIUrl":"10.1007/s11912-024-01589-4","url":null,"abstract":"Purpose of review: This document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from widespread acceptance, subsequent criminalization, to its resurgence in modern therapeutic applications, particularly within the framework of Evidence-Based Medicine (EBM).Recent findings: Anchored in EBM principles, this study synthesizes current research from clinical trials, systematic reviews, and meta-analyses to evaluate the efficacy and safety of cannabinoids in oncology. The focus is on their palliative effects, considering the nuances of effectiveness, risk assessment, and challenges inherent in translating these findings into clinical guidelines. The study seeks to bridge the gap between scientific research and clinical practice, offering insights to inform future oncological therapies and symptom management strategies involving cannabinoids. The potential benefits and risks of cannabinoid use in cancer treatment are assessed to guide clinicians and researchers in developing comprehensive, evidence-based approaches to patient care.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1334-1348"},"PeriodicalIF":4.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0